Publication

Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)

Solomon, B. J.
; 
Bauer, T. M.
; 
Felip, E.
; 
Liu, G.
; 
Mazieres, J.
; 
De Marinis, F.
; 
Goto, Y.
; 
Kim, D. W.
; 
Laktionov, K. K.
; 
Blackhall, Fiona H
... show 4 more
Citations
Altmetric:
Abstract
Authors
Solomon, B. J.
Bauer, T. M.
Felip, E.
Liu, G.
Mazieres, J.
De Marinis, F.
Goto, Y.
Kim, D. W.
Laktionov, K. K.
Blackhall, Fiona H
Dall'O, E.
Polli, A.
Toffalorio, F.
Mok, T. S. K.
Affiliation
Department of Medical Oncology and Research Division, Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Solomon BJ, Bauer TM, Felip E, Liu G, Mazieres J, De Marinis F, et al. Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302255.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625820
Embedded videos